Top

Published in:

Open Access 01-12-2010 | Research article

Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma

Authors: Osamu Shinto, Masakazu Yashiro, Takahiro Toyokawa, Takafumi Nishii, Ryoji Kaizaki, Taro Matsuzaki, Satoru Noda, Naoshi Kubo, Hiroaki Tanaka, Yosuke Doi, Masaichi Ohira, Kazuya Muguruma, Tetsuji Sawada, Kosei Hirakawa

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells. Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages.

Methods

Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas.

Results

The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly (p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2 expression was not an independence prognostic factor.

Conclusion

The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.

Available only for authorised users

Miyazono K, Suzuki H, Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci. 2003, 94 (3): 230-234. 10.1111/j.1349-7006.2003.tb01425.x.CrossRefPubMed

Massague J: TGFbeta in Cancer. Cell. 2008, 134 (2): 215-230. 10.1016/j.cell.2008.07.001.CrossRefPubMedPubMedCentral

Massague J, Seoane J, Wotton D: Smad transcription factors. Genes Dev. 2005, 19 (23): 2783-2810. 10.1101/gad.1350705.CrossRefPubMed

Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425 (6958): 577-584. 10.1038/nature02006.CrossRefPubMed

Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001, 29 (2): 117-129. 10.1038/ng1001-117.CrossRefPubMed

Moustakas A, Heldin CH: Non-Smad TGF-beta signals. J Cell Sci. 2005, 118 (Pt 16): 3573-3584. 10.1242/jcs.02554.CrossRefPubMed

Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, et al: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007, 11 (2): 147-160. 10.1016/j.ccr.2006.11.023.CrossRefPubMed

Fukuchi M, Nakajima M, Miyazaki T, Masuda N, Osawa H, Manda R, Tsukada K, Kato H, Kuwano H: Lack of activated Smad2 in transforming growth factor-beta signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2006, 94 (1): 51-56. 10.1002/jso.20565.CrossRefPubMed

Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M: Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002, 62 (2): 497-505.PubMed

10.

Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M: Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J. 2003, 9 (4): 302-312. 10.1097/00130404-200307000-00013.CrossRefPubMed

11.

Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000, 20 (6B): 4489-4493.PubMed

12.

Lin Y, Kikuchi S, Obata Y, Yagyu K: Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol. 2006, 21 (2): 432-437. 10.1111/j.1440-1746.2005.03939.x.CrossRefPubMed

13.

Japanese Gastric Cancer A: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1998, 1 (1): 10-24.CrossRef

14.

Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer. 102 (5): 844-851. 10.1038/sj.bjc.6605561.

15.

Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11 (2): 155-168.PubMed

16.

Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80 (9): 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.CrossRefPubMed

17.

Lauren P: The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965, 64: 31-49.PubMed

18.

Nakazawa K, Yashiro M, Hirakawa K: Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003, 63 (24): 8848-8852.PubMed

19.

Fujihara T, Yashiro M, Inoue T, Sawada T, Kato Y, Ohira M, Nishiguchi Y, Ishikawa T, Sowa M, Chung KH: Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis. Gastric Cancer. 1999, 2 (4): 221-225. 10.1007/s101200050067.CrossRefPubMed

20.

Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H: Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001, 61 (3): 889-895.PubMed

21.

Yashiro M, Chung YS, Kubo T, Hato F, Sowa M: Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer. 1996, 74 (7): 1096-1103.CrossRefPubMedPubMedCentral

22.

Tendo M, Yashiro M, Nakazawa K, Yamada N, Hirakawa K: Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer Sci. 2005, 96 (7): 451-455. 10.1111/j.1349-7006.2005.00066.x.CrossRefPubMed

23.

Takemura S, Yashiro M, Sunami T, Tendo M, Hirakawa K: Novel models for human scirrhous gastric carcinoma in vivo. Cancer Sci. 2004, 95 (11): 893-900. 10.1111/j.1349-7006.2004.tb02199.x.CrossRefPubMed

24.

Kinugasa S, Abe S, Tachibana M, Hishikawa Y, Yoshimura H, Monden N, Dhar DK, Nagasue N, Nagaoka S: Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology. 1998, 55 (6): 582-587. 10.1159/000011916.CrossRefPubMed

25.

Mahara K, Kato J, Terui T, Takimoto R, Horimoto M, Murakami T, Mogi Y, Watanabe N, Kohgo Y, Niitsu Y: Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. British journal of cancer. 1994, 69 (4): 777-783.CrossRefPubMedPubMedCentral

26.

Yoshida K, Yokozaki H, Niimoto M, Ito H, Ito M, Tahara E: Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. International journal of cancer. 1989, 44 (3): 394-398. 10.1002/ijc.2910440303.CrossRefPubMed

27.

Yang L, Moses HL: Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?. Cancer research. 2008, 68 (22): 9107-9111. 10.1158/0008-5472.CAN-08-2556.CrossRefPubMedPubMedCentral

28.

Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, et al: A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res. 2008, 14 (9): 2850-2860. 10.1158/1078-0432.CCR-07-1634.CrossRefPubMed

29.

Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, et al: Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA. 2007, 104 (9): 3460-3465. 10.1073/pnas.0611660104.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/652/prepub

Title: Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma
Authors: Osamu Shinto
Masakazu Yashiro
Takahiro Toyokawa
Takafumi Nishii
Ryoji Kaizaki
Taro Matsuzaki
Satoru Noda
Naoshi Kubo
Hiroaki Tanaka
Yosuke Doi
Masaichi Ohira
Kazuya Muguruma
Tetsuji Sawada
Kosei Hirakawa
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-652

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Mammographic density and markers of socioeconomic status: a cross-sectional study

Metastatic lymph node in gastric cancer; Is it a real distant metastasis?

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures

Keynote webinar | Spotlight on antibody–drug conjugates in cancer